Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+
Puma Biotechnology (NASDAQ:PBYI) Upgraded to Buy by Citigroup - Opera News
Puma Biotechnology Reports Third Quarter 2021 Financial Results | Business Wire
European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
ST – Puma Biotechnology Partnership - Specialised Therapeutics
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
puma biotechnology stock news Off 62% - canerofset.com
Puma Biotechnology
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
PumaBiotech (@pumabiotech) / Twitter
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology - Crunchbase Company Profile & Funding
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Puma Biotechnology Surging
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology wins extension for U.S. patent related to breast cancer therapy | Seeking Alpha
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib – Pharma News HQ
